CNS Pharmaceuticals, Inc. (CNSP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in CNS Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

CNS Pharmaceuticals, Inc. (CNSP) has returned -54.48% so far this year and -85.36% over the past 12 months.

Based on dividend-adjusted daily data since Nov 8, 2019, CNSP's average daily return is -0.52%, while the average monthly return is -11.48%.

Historically, 26% of months were positive and 74% were negative. The best month was Oct 2023 with a return of +81.6%, while the worst month was Jun 2024 at -85.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 13 months.

On a daily basis, CNSP closed higher 41% of trading days. The best single day was Apr 14, 2023 with a return of +243.1%, while the worst single day was Jul 30, 2024 at -60.6%.

CNS Pharmaceuticals, Inc. has an annualized alpha of -75.96%, beta of 0.81, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 11, 2019.

• This stock participated in 233.87% of S&P 500 Index downside but only -146.62% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CNSP ranks 4 for risk / return — in the bottom 4% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for CNS Pharmaceuticals, Inc. (CNSP) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CNS Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CNS Pharmaceuticals, Inc. was 100.00%, occurring on Mar 19, 2026. The portfolio has not yet recovered.

The current CNS Pharmaceuticals, Inc. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of CNS Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how CNS Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.